Editing Hypoglycemia (section)

=== Other treatments ===
While the treatment of hypoglycemia is typically managed with carbohydrate consumption, glucagon injection, or [[dextrose]] administration, there are some other treatments available.<ref name="Jameson_2018" /> Medications like [[diazoxide]] and [[octreotide]] decrease insulin levels, increasing blood glucose levels.<ref name="Jameson_2018" /> [[Dasiglucagon]] was approved for medical use in the United States in March 2021, to treat severe hypoglycemia.<ref name="Zegalogue FDA label">{{Cite web |title=HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use ZEGALOGUE® safely and effectively. See full prescribing information for ZEGALOGUE. ZEGALOGUE (dasiglucagon) injection, for subcutaneous use. |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf |url-status=live |archive-url=https://web.archive.org/web/20210515201935/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf |archive-date=15 May 2021 |access-date=10 November 2021 |website=Accessdate.fsa.gov}}</ref> Dasiglucagon (brand name Zegalogue) is unique because it is glucagon in a prefilled syringe or auto-injector pen, as opposed to traditional glucagon kits that require mixing powdered glucagon with a liquid.<ref name="Zegalogue FDA label" />

Due to its original formulation containing large amounts of glucose, the soft drink [[Lucozade]] was recommended by diabetes charities in the [[United Kingdom]] as an immediate treatment for hypoglycemia; however, as the drink was reformulated to replace much of its glucose content with [[artificial sweeteners]], this is no longer recommended.<ref>{{Cite web |title=Diabetic patients should be warned about changes to Lucozade glucose content |url=https://www.nursinginpractice.com/article/diabetic-patients-should-be-warned-about-changes-lucozade-glucose-content |url-status=dead |archive-url=https://web.archive.org/web/20190228070127/https://www.nursinginpractice.com/article/diabetic-patients-should-be-warned-about-changes-lucozade-glucose-content |archive-date=28 February 2019 |access-date=27 February 2019 |website=[[Nursing in Practice]] |vauthors=Harrold A}}</ref>